Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
42.02
+0.80 (1.94%)
At close: Dec 20, 2024, 4:00 PM
43.00
+0.98 (2.33%)
After-hours: Dec 20, 2024, 5:29 PM EST

Verona Pharma Statistics

Total Valuation

Verona Pharma has a market cap or net worth of $3.44 billion. The enterprise value is $3.22 billion.

Market Cap 3.44B
Enterprise Value 3.22B

Important Dates

The last earnings date was Monday, November 4, 2024, before market open.

Earnings Date Nov 4, 2024
Ex-Dividend Date n/a

Share Statistics

Verona Pharma has 81.83 million shares outstanding. The number of shares has increased by 3.55% in one year.

Current Share Class n/a
Shares Outstanding 81.83M
Shares Change (YoY) +3.55%
Shares Change (QoQ) +0.57%
Owned by Insiders (%) 4.10%
Owned by Institutions (%) 63.88%
Float 50.15M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS 25.99
PB Ratio 26.35
P/TBV Ratio 26.46
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 573.40
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 13.03, with a Debt / Equity ratio of 0.94.

Current Ratio 13.03
Quick Ratio 12.47
Debt / Equity 0.94
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -10.93

Financial Efficiency

Return on equity (ROE) is -78.03% and return on invested capital (ROIC) is -35.24%.

Return on Equity (ROE) -78.03%
Return on Assets (ROA) -28.05%
Return on Capital (ROIC) -35.24%
Revenue Per Employee $71,190
Profits Per Employee -$1.95M
Employee Count 79
Asset Turnover 0.02
Inventory Turnover n/a

Taxes

In the past 12 months, Verona Pharma has paid $1.97 million in taxes.

Income Tax 1.97M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +140.39% in the last 52 weeks. The beta is 0.43, so Verona Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.43
52-Week Price Change +140.39%
50-Day Moving Average 37.57
200-Day Moving Average 24.30
Relative Strength Index (RSI) 60.87
Average Volume (20 Days) 938,322

Short Selling Information

Short Interest 6.36M
Short Previous Month 5.98M
Short % of Shares Out 8.11%
Short % of Float n/a
Short Ratio (days to cover) 5.44

Income Statement

In the last 12 months, Verona Pharma had revenue of $5.62 million and -$153.72 million in losses. Loss per share was -$1.93.

Revenue 5.62M
Gross Profit 5.08M
Operating Income -151.30M
Pretax Income -123.69M
Net Income -153.72M
EBITDA -150.30M
EBIT -151.30M
Loss Per Share -$1.93
Full Income Statement

Balance Sheet

The company has $336.04 million in cash and $122.31 million in debt, giving a net cash position of $213.73 million or $2.61 per share.

Cash & Cash Equivalents 336.04M
Total Debt 122.31M
Net Cash 213.73M
Net Cash Per Share $2.61
Equity (Book Value) 130.49M
Book Value Per Share 1.59
Working Capital 336.30M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$103.77 million and capital expenditures -$45,000, giving a free cash flow of -$103.81 million.

Operating Cash Flow -103.77M
Capital Expenditures -45,000
Free Cash Flow -103.81M
FCF Per Share -$1.27
Full Cash Flow Statement

Margins

Gross Margin 90.34%
Operating Margin -2,690.33%
Pretax Margin -2,698.40%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Verona Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -3.55%
Shareholder Yield -3.55%
Earnings Yield -4.47%
FCF Yield -3.02%
Dividend Details

Analyst Forecast

The average price target for Verona Pharma is $43.83, which is 4.31% higher than the current price. The consensus rating is "Strong Buy".

Price Target $43.83
Price Target Difference 4.31%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Verona Pharma has an Altman Z-Score of 1.36 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.36
Piotroski F-Score 3